Annual SG&A
$76.16 M
-$26.30 M-25.67%
31 December 2023
Summary:
CRISPR Therapeutics AG annual selling, general & administrative expenses is currently $76.16 million, with the most recent change of -$26.30 million (-25.67%) on 31 December 2023. During the last 3 years, it has fallen by -$12.05 million (-13.66%). CRSP annual SG&A is now -25.67% below its all-time high of $102.46 million, reached on 31 December 2022.CRSP Selling, General & Administrative Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly SG&A
$17.42 M
-$2.06 M-10.58%
30 September 2024
Summary:
CRISPR Therapeutics AG quarterly selling, general & administrative expenses is currently $17.42 million, with the most recent change of -$2.06 million (-10.58%) on 30 September 2024. Over the past year, it has dropped by -$872.00 thousand (-4.77%). CRSP quarterly SG&A is now -39.53% below its all-time high of $28.81 million, reached on 30 June 2021.CRSP Quarterly SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM SG&A
-$4.69 B
-$239.59 M-5.39%
30 September 2024
Summary:
CRISPR Therapeutics AG TTM selling, general & administrative expenses is currently -$4.69 billion, with the most recent change of -$239.59 million (-5.39%) on 30 September 2024. Over the past year, it has dropped by -$4.77 billion (-5897.42%). CRSP TTM SG&A is now -13724.49% below its all-time high of $104.97 million, reached on 30 September 2022.CRSP TTM SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
CRSP Selling, General & Administrative Expenses Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -25.7% | -4.8% | -5897.4% |
| 3 y3 years | -13.7% | -26.5% | -4659.8% |
| 5 y5 years | +57.7% | +12.2% | -7568.9% |
CRSP Selling, General & Administrative Expenses High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -25.7% | at low | -37.8% | +5.7% | -747.3% | at low |
| 5 y | 5 years | -25.7% | +57.7% | -39.5% | +12.2% | -747.3% | at low |
| alltime | all time | -25.7% | +1389.3% | -39.5% | +610.1% | <-9999.0% | at low |
CRISPR Therapeutics AG Selling, General & Administrative Expenses History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $17.42 M(-10.6%) | $71.33 M(-1.2%) |
| June 2024 | - | $19.48 M(+8.5%) | $72.20 M(+0.6%) |
| Mar 2024 | - | $17.95 M(+8.9%) | $71.75 M(-5.8%) |
| Dec 2023 | $76.16 M(-25.7%) | $16.48 M(-9.9%) | $76.16 M(-5.8%) |
| Sept 2023 | - | $18.29 M(-3.9%) | $80.85 M(-9.7%) |
| June 2023 | - | $19.03 M(-14.9%) | $89.56 M(-7.5%) |
| Mar 2023 | - | $22.36 M(+5.6%) | $96.80 M(-5.5%) |
| Dec 2022 | $102.46 M(+2.8%) | $21.17 M(-21.6%) | $102.46 M(-2.4%) |
| Sept 2022 | - | $27.00 M(+2.8%) | $104.97 M(+3.2%) |
| June 2022 | - | $26.27 M(-6.2%) | $101.68 M(-2.4%) |
| Mar 2022 | - | $28.02 M(+18.3%) | $104.21 M(+3.5%) |
| Dec 2021 | $99.69 M(+13.0%) | $23.68 M(-0.1%) | $100.71 M(-2.0%) |
| Sept 2021 | - | $23.71 M(-17.7%) | $102.80 M(+2.2%) |
| June 2021 | - | $28.81 M(+17.5%) | $100.63 M(+8.0%) |
| Mar 2021 | - | $24.52 M(-4.8%) | $93.17 M(+5.6%) |
| Dec 2020 | $88.21 M(+38.9%) | $25.77 M(+19.6%) | $88.21 M(+10.7%) |
| Sept 2020 | - | $21.54 M(+0.9%) | $79.71 M(+8.2%) |
| June 2020 | - | $21.35 M(+9.2%) | $73.69 M(+8.2%) |
| Mar 2020 | - | $19.55 M(+13.2%) | $68.11 M(+7.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2019 | $63.49 M(+31.5%) | $17.27 M(+11.3%) | $63.49 M(+1.2%) |
| Sept 2019 | - | $15.52 M(-1.6%) | $62.76 M(+9.3%) |
| June 2019 | - | $15.77 M(+5.6%) | $57.41 M(+5.6%) |
| Mar 2019 | - | $14.93 M(-9.8%) | $54.39 M(+12.6%) |
| Dec 2018 | $48.29 M(+34.7%) | $16.54 M(+62.6%) | $48.29 M(+12.1%) |
| Sept 2018 | - | $10.18 M(-20.1%) | $43.08 M(+5.0%) |
| June 2018 | - | $12.74 M(+44.2%) | $41.01 M(+13.8%) |
| Mar 2018 | - | $8.84 M(-22.0%) | $36.04 M(+0.5%) |
| Dec 2017 | $35.84 M(+15.4%) | $11.32 M(+39.6%) | $35.84 M(-2.1%) |
| Sept 2017 | - | $8.11 M(+4.4%) | $36.60 M(+12.3%) |
| June 2017 | - | $7.77 M(-10.1%) | $32.60 M(-2.9%) |
| Mar 2017 | - | $8.64 M(-28.5%) | $33.58 M(+8.1%) |
| Dec 2016 | $31.06 M(+131.7%) | $12.08 M(+194.2%) | $31.06 M(+23.2%) |
| Sept 2016 | - | $4.11 M(-53.1%) | $25.21 M(+7.0%) |
| June 2016 | - | $8.75 M(+43.1%) | $23.56 M(+59.1%) |
| Mar 2016 | - | $6.12 M(-2.0%) | $14.81 M(+70.4%) |
| Dec 2015 | $13.40 M(+162.1%) | $6.24 M(+154.3%) | $8.69 M(+254.3%) |
| Sept 2015 | - | $2.45 M | $2.45 M |
| Dec 2014 | $5.11 M | - | - |
FAQ
- What is CRISPR Therapeutics AG annual selling, general & administrative expenses?
- What is the all time high annual SG&A for CRISPR Therapeutics AG?
- What is CRISPR Therapeutics AG annual SG&A year-on-year change?
- What is CRISPR Therapeutics AG quarterly selling, general & administrative expenses?
- What is the all time high quarterly SG&A for CRISPR Therapeutics AG?
- What is CRISPR Therapeutics AG quarterly SG&A year-on-year change?
- What is CRISPR Therapeutics AG TTM selling, general & administrative expenses?
- What is the all time high TTM SG&A for CRISPR Therapeutics AG?
- What is CRISPR Therapeutics AG TTM SG&A year-on-year change?
What is CRISPR Therapeutics AG annual selling, general & administrative expenses?
The current annual SG&A of CRSP is $76.16 M
What is the all time high annual SG&A for CRISPR Therapeutics AG?
CRISPR Therapeutics AG all-time high annual selling, general & administrative expenses is $102.46 M
What is CRISPR Therapeutics AG annual SG&A year-on-year change?
Over the past year, CRSP annual selling, general & administrative expenses has changed by -$26.30 M (-25.67%)
What is CRISPR Therapeutics AG quarterly selling, general & administrative expenses?
The current quarterly SG&A of CRSP is $17.42 M
What is the all time high quarterly SG&A for CRISPR Therapeutics AG?
CRISPR Therapeutics AG all-time high quarterly selling, general & administrative expenses is $28.81 M
What is CRISPR Therapeutics AG quarterly SG&A year-on-year change?
Over the past year, CRSP quarterly selling, general & administrative expenses has changed by -$872.00 K (-4.77%)
What is CRISPR Therapeutics AG TTM selling, general & administrative expenses?
The current TTM SG&A of CRSP is -$4.69 B
What is the all time high TTM SG&A for CRISPR Therapeutics AG?
CRISPR Therapeutics AG all-time high TTM selling, general & administrative expenses is $104.97 M
What is CRISPR Therapeutics AG TTM SG&A year-on-year change?
Over the past year, CRSP TTM selling, general & administrative expenses has changed by -$4.77 B (-5897.42%)